MannKind
Manufacturing · Connecticut, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1 Casper St, Danbury, Connecticut, 06810...Phone Number
(818) 661-5000Website
www.mannkindcorp.comRevenue
$393.6 MillionStock Symbol
MNKDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
2
1
1
1
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MannKind your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if MannKind had a recent Job posting/layoffs
Earning: See what the market has to say on MannKind recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at MannKind
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when MannKind launches new products
Check if MannKind has recently received funding, and reach out quickly before it becomes old news!
MannKind, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once MannKind has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if MannKind is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined MannKind as Masked Content
Find more new buyers
Compare Similar Companies to MannKind
Compare insights from companies similar to MannKind, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MannKind is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MannKind is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MannKind.
MannKind financials insights
Gather financial insights about MannKind, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$36.2M
2016
Stock Offering
$47.5M
2017
Stock Offering
$61M
2018
Stock Offering
$28M
2020
Debt
$2M
2025
Stock/Share Issuance
$500M
2026
Stock/Share Issuance
$50M
MannKind Tech Stack
A closer look at the technologies used by MannKind
See more technologies
Most Recent Scoops
Project
MannKind has reported that, within the first eight weeks of the Afrezza pediatric launch, one in three of the top 100 pediatric rapid-acting insulin writers have already prescribed Afrezza, and all 20 priority accounts have written at least one prescription since launch.
Pharmaceuticals
Project
MannKind has reported that its Phase I-B study of nintedanib DPI in patients with underlying idiopathic pulmonary fibrosis (IPF) a 2-cohort, multiple-ascending dose study evaluating 2 mg three times daily and 4 mg twice daily demonstrated zero safety signals, zero bronchospasms, and zero discontinuations or dose reductions, supporting the program's advancement into Phase II.
Medical Research, Pharmaceuticals
Product Launch
MannKind has announced that the FUROSCIX ReadyFlow, the only IV-equivalent diuretic delivered via autoinjector, will be available to key institutions and community prescribers within three weeks, with a safety profile consistent with oral and IV furosemide and potential symptom relief beginning within one hour.
Pharmaceuticals
Product Launch
MannKind has announced the launch of the FUROSCIX ReadyFlow autoinjector, an FDA-approved device targeting post-hospital discharge heart failure management, aimed at enabling earlier patient discharge, reducing 30-day hospital readmissions, and expanding post-discharge treatment protocols across major U.S. health systems.
Product Launch
Product Launch
Advertising, Marketing Campaign, Public Relations
MannKind News & Media
First Trust Advisors LP Raises Stake in MannKind Corporation $MNKD - MarketBeat
First Trust Advisors LP boosted its position in shares of MannKind Corporation (NASDAQ:MNKD - Free Report) by 48.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 869,254 shares of the biopharmaceutical companMannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsMichael Castagna - CEO & DirectorChristopher Prentiss -...MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the second quarter of 2026, and provided a business update.MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF July 29, 2026 4:30 PM EDTCompany ParticipantsMichael...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MannKind
Sign Up For FreeTo access detailed company insights
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery dev... Read More
